VPS35 and Parkinson disease: Knock-in mice carrying the Parkinson’s disease-associated Vps35-D620N mutation have a significant reduction in evoked DA release by microdialysis in the absence of neurodegeneration and in the presence of normal DA synthesis at 20–28 weeks old (Table 1).49 A further Vps35-D630N knock-in mouse model was reported to have an early (at 3 months) increase in evoked DA release by FCV.50